Search Results

< Prev
1 of 1
Next >

News Releases

17:21 ET

Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 38th Annual Healthcare Conference on Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, Boston, beginning at 9:20 a.m. Eastern Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present at the...

More news about: Amgen
May 22, 2013, 17:46 ET

Amgen Announces Voting Results of Annual Meeting of Stockholders

Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 87.80 percent of outstanding shares were represented at the meeting. The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A....

More news about: Amgen
May 16, 2013, 16:18 ET

Amgen To Present At The UBS Global Life Sciences Conference

Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development...

More news about: Amgen , UBS Global Life Sciences Conference
May 16, 2013, 09:30 ET

The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Genomic Health Inc. (Nasdaq:GHDX), Sanofi (NYSE:SNY),...

More news about: Zacks Investment Research, Inc. , Genomic Health Inc. , Sanofi , Regeneron Pharmaceuticals, Inc. , Amgen Inc. , Isis Pharmaceuticals, Inc.
May 15, 2013, 18:02 ET

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive...

More news about: Amgen
May 15, 2013, 18:00 ET

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate...

More news about: Amgen , 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
May 14, 2013, 08:00 ET

Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States

The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing...

More news about: Thomson Reuters , Amgen , Sandoz , Hospira
May 09, 2013, 16:08 ET

Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to...

More news about: Amgen , Amgen-Beta Pharmaceuticals Co., Ltd. , Zhejiang Beta Pharma Co., Ltd.
May 07, 2013, 16:04 ET

Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer

Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors...

More news about: Amgen
May 01, 2013, 16:05 ET

Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California

Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer® Champions. They will be honored as part of Amgen's Breakaway from Cancer initiative at the eighth consecutive edition of the...

More news about: Amgen
Apr 23, 2013, 16:00 ET

Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include: - Total revenues increased 5 percent to $4,238 million, with 6 percent product sales growth driven by Enbrel® (etanercept), XGEVA® (denosumab) and...

More news about: Amgen
Apr 23, 2013, 09:31 ET

Critical Alerts For Amgen, Peabody Energy, CME, MDC Holdings, and Hanesbrands Released By InvestorsObserver

InvestorsObserver issues critical PriceWatch Alerts for AMGN, BTU, CME, MDC, and HBI. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at...

More news about: InvestorsObserver , Amgen , Peabody Energy , CME , MDC Holdings , Hanesbrands
Apr 18, 2013, 16:16 ET

Amgen Announces Webcast of 2013 First Quarter Financial Results

Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Daylight Time....

More news about: Amgen
Apr 04, 2013, 08:50 ET

Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures

Amgen Inc. (NASDAQ: AMGN), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) today joined thirteen institutional investors in endorsing a set of principles aimed at deterring...

More news about: UAW Retiree Medical Benefits Trust , Amgen Inc. , Bristol-Myers Squibb Company , Eli Lilly and Company , Johnson & Johnson , Merck & Co., Inc. , Pfizer Inc.